Back to Faculty
Faculty

Helena Yu

MD
Associate Attending
Memorial Sloan Kettering Cancer Center

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.

2026 Sessions

Evolving Strategies in EGFR-Mutated Non-Small Cell Lung Cancer: Translating Molecular Insights into Clinical Decision-Making

Supported by an educational grant from Johnson & Johnson.

Presenter

Saturday, March 14 10:25–11:10 AM
Room Royal Ballroom 3/4
Faculty

Helena Yu

MD
Associate Attending
Memorial Sloan Kettering Cancer Center

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.

Evolving Strategies in EGFR-Mutated Non-Small Cell Lung Cancer: Translating Molecular Insights into Clinical Decision-Making

Supported by an educational grant from Johnson & Johnson.

Presenter

Saturday, September 26 10:50–11:35 AM
Faculty

Helena Yu

MD
Associate Attending
Memorial Sloan Kettering Cancer Center

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.

Monotherapy Approaches

Faculty will contrast monotherapy approaches with emerging combination strategies in the optimal first-line treatment of NSCLC and examine whether combining targeted agents with additional modalities improves long-term outcomes. The discussion will highlight efficacy, toxicity, resistance patterns, and sequencing considerations across available approaches. Presenters will provide expert perspective on integrating evolving clinical evidence into real-world treatment decisions.

Debate Speaker

Saturday, September 26 3:30–3:50 PM
Faculty

Helena Yu

MD
Associate Attending
Memorial Sloan Kettering Cancer Center

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.
General Session

First-Line Strategies in EGFR-Mutated Metastatic Non-Small Cell Lung Cancer: Monotherapy Approaches vs Combination Approaches

Faculty will contrast monotherapy approaches with emerging combination strategies in the optimal first-line treatment of NSCLC and examine whether combining targeted agents with...

  • Moderator
    • Edward Garon, MD, MS
    • Corey Langer, MD, FACP
  • Presenter
    • Eric Singhi, MD
    • Helena Yu, MD
Lung Cancers

Monotherapy Approaches

Faculty will contrast monotherapy approaches with emerging combination strategies in the optimal first-line treatment of NSCLC and examine whether combining targeted agents with additional modalities improves long-term outcomes. The discussion will highlight efficacy, toxicity, resistance patterns, and sequencing considerations across available approaches. Presenters will provide expert perspective on integrating evolving clinical evidence into real-world treatment decisions.

Debate Speaker

Saturday, September 26 3:30–3:50 PM
Faculty

Helena Yu

MD
Associate Attending
Memorial Sloan Kettering Cancer Center

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.

Combination Approaches

Faculty will contrast monotherapy approaches with emerging combination strategies in the optimal first-line treatment of NSCLC and examine whether combining targeted agents with additional modalities improves long-term outcomes. The discussion will highlight efficacy, toxicity, resistance patterns, and sequencing considerations across available approaches. Presenters will provide expert perspective on integrating evolving clinical evidence into real-world treatment decisions.

Debate Speaker

Saturday, September 26 3:50–4:10 PM
Faculty

Eric Singhi

MD
Assistant Professor
MD Anderson Cancer Center

Dr. Eric K. Singhi is an Assistant Professor and Thoracic Medical Oncologist at the University of Texas MD Anderson Cancer Center. He completed his Internal Medicine residency at Vanderbilt University and served as Chief Hematology/Oncology fellow at MD Anderson during his training.

As faculty at MD Anderson, Dr. Singhi specializes in patient education research and young onset lung cancer research. He serves as the medical oncology lead for the MD Anderson Young-Onset Lung Cancer Program, Patient Safety and Quality Officer for the Thoracic Medical Oncology Service Line, Director of Thoracic Research for the MD Anderson Cancer Network, and Director of the Thoracic Medical Oncology rotation for the MD Anderson medical oncology fellowship program. Nationally, he serves on the ASCO NSCLC Guidelines Committee, and Internationally on the IASLC Communications Committee.
Back to top